Status:
RECRUITING
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
Lead Sponsor:
AstraZeneca
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemother...
Detailed Description
This study is an observational, bi-directional (prospective and retrospective) analytical study designed to assess the sociodemographic, clinical, and pathological characteristics of patients with ova...
Eligibility Criteria
Inclusion
- Patients ≥18 years old;
- Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
- Irrespective of histology
Exclusion
- Borderline tumors;
- Pregnancy;
- Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);
Key Trial Info
Start Date :
September 19 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT07167433
Start Date
September 19 2025
End Date
March 31 2026
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Porto Alegre, Brazil